ACTIVE

Center for Beta Cell Therapy in Diabetes

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result-219,3 k €-71,0 %over 1 year

Gross margin-184,4 k €-97,6 %over 1 year

Equity2,6 M €-7,7 %over 1 year

Workforce0,1 ETP0,0 %over 1 year

Identity

Source · BCE/KBO

Center for Beta Cell Therapy in Diabetes is a Non-profit organization incorporated in 2005. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Jette. It employs on average 0,1 ETP workers (FTE).

Legal situation: Normal situation
BCE/KBO no. / VAT: BE 0872.566.468
Incorporation: 17/03/2005
Legal form: Non-profit organization
Registered office: Avenue du Laerbeek 103
1090 Jette · BruxellesSee on map
Latest accounts: 31/12/2025
Average workforce: 0,1 ETP

Activities (NACE)

72109Research and experimental development on natural sciences and engineering· main 72190Other research and experimental development on natural sciences and engineering 73100Advertising

Joint committees (1)

Signals

Solid equityLow riskGood liquidityHealthy social debts

Financials

Source · NBB, 20 filings

Trend over 19 financial years

	2025		2024		2023		2022		2021
Income statement
Gross margin	-184,4 k €	-97.6%	-93,3 k €	+53.3%	-199,8 k €	+2.9%	-205,9 k €	-220%	-64,3 k €
EBITDA	-214,3 k €	-72.3%	-124,4 k €	+46.2%	-231 k €	+2.2%	-236,2 k €	-155%	-92,5 k €
Operating result	-215,3 k €	-73.1%	-124,4 k €	+46.2%	-231 k €	+2.2%	-236,2 k €	-155%	-92,5 k €
Net result	-219,3 k €	-71.0%	-128,3 k €	-629%	-17,6 k €	+96.6%	-520,2 k €	-328%	228,1 k €
Balance sheet
Equity	2,6 M €	-7.7%	2,8 M €	-4.3%	3 M €	-0.6%	3 M €	-14.8%	3,5 M €
Total assets	3,2 M €	-4.7%	3,3 M €	+2.1%	3,2 M €	-0.3%	3,3 M €	-14.2%	3,8 M €
Cash	141,2 k €	-66.8%	425,7 k €	-37.4%	679,8 k €	-8.8%	745,5 k €	+4.3%	714,4 k €
Debts	10,5 k €	-86.0%	75,4 k €	-63.5%	206,5 k €	-23.3%	269,3 k €	+33.2%	202,1 k €
Other
Workforce	0,1 ETP	0.0%	0,1 ETP	-50.0%	0,2 ETP	0.0%	0,2 ETP	0.0%	0,2 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 2,5 M€ and 5 M€

See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

3 active · 10 ended

Active mandates

Bart Keymeulen

Director

Active

Daniël Pipeleers

Chairman of the board of directors

Active

Sabrina Uyttenhove

Director

Active

Ended mandates

Sabrina Uyttenhove

Director · since 01 juin 2012

Ended

Chris Vangeneugden

Director · until 01 juillet 2010

Ended

Chris Vangeneugden

Director

Ended

Christel Hendrieckx

Director · until 01 juin 2012

Ended

Other companies at this address

Avenue du Laerbeek 103 1090 Jette

Company	CBE no.
Diabetes Research Fonds● Active	0447.689.840
Huis van de Geneeskundige Kring V.U.B.● Active	0423.468.742
Palliatief Netwerk Omega● Active	0435.563.850
Société belge des Physiciens des Hôpitaux - Belgische Vereniging van Ziekenhuisfysici● Active	0418.717.227
vzw Vlaams Farmaceutisch Studenten Overleg● Active	0563.649.578

Full financial information

Source · NBB

	2025	2024	2023	2022	2021	2020
Type of account	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	24/07/2026	23/04/2025	11/06/2024	10/05/2023	21/04/2022	19/04/2021
General meeting	30/03/2026	01/04/2025	27/03/2024	24/03/2023	29/03/2022	24/03/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 20 filings

Model	Closing	General meeting	Filed	Language	Document
Abridged model	31/12/2025	30/03/2026	24/07/2026	Dutch	PDF
Abridged model	31/12/2024	01/04/2025	23/04/2025	Dutch	PDF
Abridged model	31/12/2023	27/03/2024	11/06/2024	Dutch	PDF
Abridged model	31/12/2022	24/03/2023	10/05/2023	Dutch	PDF
Abridged model	31/12/2021	29/03/2022	21/04/2022	Dutch	PDF
Abridged model	31/12/2020	24/03/2021	19/04/2021	Dutch	PDF
Abridged model	31/12/2019	24/03/2020	02/06/2020	Dutch	PDF
Abridged model	31/12/2018	21/03/2019	18/06/2019	Dutch	PDF
Abridged model	31/12/2017	15/03/2018	24/09/2018	Dutch	PDF
Abridged model	31/12/2016	20/06/2017	21/06/2017	Dutch	PDF
Abridged model	31/12/2015	28/06/2016	03/08/2016	Dutch	PDF
Abridged model	31/12/2014	29/06/2015	22/09/2015	Dutch	PDF
Abridged model	31/12/2013	25/06/2014	27/06/2014	Dutch	PDF
Abridged model	31/12/2012	26/06/2013	02/07/2013	Dutch	PDF
Abridged model	31/12/2011	26/06/2012	28/06/2012	Dutch	PDF
Abridged model	31/12/2010	27/06/2011	30/06/2011	Dutch	PDF
Abridged model	31/12/2009	28/06/2010	30/08/2010	Dutch	PDF
Abridged model	31/12/2008	12/06/2009	23/07/2009	Dutch	PDF
Abridged model	31/12/2007	23/06/2008	27/06/2008	Dutch	PDF
Abridged model	31/12/2006	20/06/2007	06/07/2007	Dutch	PDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 2,5 M€ and 5 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

3 active · 10 ended

Active mandates

Bart Keymeulen

Director

Active

Daniël Pipeleers

Chairman of the board of directors

Active

Sabrina Uyttenhove

Director

Active

Ended mandates

Sabrina Uyttenhove

Director · since 01 juin 2012

Ended

Chris Vangeneugden

Director · until 01 juillet 2010

Ended

Chris Vangeneugden

Director

Ended

Christel Hendrieckx

Director · until 01 juin 2012

Ended

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette

Mandates09/01/2015
ONTSLAGEN - BENOEMINGEN
PDF
Mandates19/07/2011
BENAMING - ONTSLAGEN - BENOEMINGEN - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, )
PDF
Mandates28/07/2010
ONTSLAGEN - BENOEMINGEN
PDF
Other29/03/2005
RUBRIEK OPRICHTING (NIEUWE RECHTSPERSOON, OPENING BIJKANTOOR, ENZ...)
PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

2025
Annual accounts 2025-219,3 k €↓
2024
Annual accounts 2024-128,3 k €↓
2023
Annual accounts 2023-17,6 k €↑
2022
Annual accounts 2022-520,2 k €↓
2021
Annual accounts 2021228,1 k €↑
2020
Annual accounts 202094,2 k €↑
2019
Annual accounts 201963 k €↑
2018
Annual accounts 2018-97,5 k €↓
2017
Annual accounts 2017-68,1 k €↓
2016
Annual accounts 2016269,5 k €↑
2015
Annual accounts 2015-170,6 k €↓
2014
Annual accounts 2014104,2 k €↓
2013
Annual accounts 2013232,5 k €↑
2012
Annual accounts 2012128,8 k €↑
2011
Annual accounts 201127,6 k €↑
2010
Annual accounts 2010-34,4 k €↓
2010
Name changeCenter for Beta Cell Therapy in Diabetes
2009
Annual accounts 2009120,7 k €↑
2008
Annual accounts 2008-312 k €↓
2007
Annual accounts 2007239,6 k €
2007
Name changeJuvenile Diabetes Research Foundation Center for Beta Cell Therapy in Diabetes
17/03/2005
IncorporationNon-profit organization

Center for Beta Cell Therapy in Diabetes

Overview

Identity

Financials

Valuation

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline

Timeline